Identifying patients with familial hypercholesterolemia using data mining methods in the Northern Great Plain region of Hungary by Paragh, György et al.
                             Elsevier Editorial System(tm) for 
Atherosclerosis 
                                  Manuscript Draft 
 
 
Manuscript Number: ATH-D-18-00393R1 
 
Title: Identifying patients with familial hypercholesterolemia using data 
mining methods in the Northern Great Plain region of Hungary  "FH Special 
issue"  
 
Article Type: Research paper 
 
Section/Category: Clinical & Population Research 
 
Keywords: Familial hypercholesterolemia; screening; low-density 
lipoprotein; Dutch Lipid Clinic Network Criteria; data mining; deep 
learning 
 
Corresponding Author: Professor György Paragh,  
 
Corresponding Author's Institution: University of Debrecen 
 
First Author: György Paragh 
 
Order of Authors: György Paragh; Mariann Harangi; Zsolt Karányi; Bálint 
Daróczy; Ákos Németh; Péter Fülöp 
 
Abstract: Background and aims: Familial hypercholesterolemia (FH) is one 
of the most frequent diseases with monogenic inheritance. Previous data 
indicated that the heterozygous form occurred in 1:250 people. Based on 
these reports, around 36 000-40 000 people are estimated to have FH in 
Hungary, however, there are no exact data about the frequency of the 
disease in our country. Therefore, we initiated a cooperation with a 
clinical site partner company that provides modern data mining methods on 
the basis of medical and statistical records and we applied them on two 
major hospitals in the Northern Great Plain region of Hungary to find 
patients with a possible diagnosis of FH.  
Methods: Medical records of 1 342 124 patients were included our study. 
From the mined data, we calculated Dutch Lipid Clinic Network (DLCN) 
scores for each patient and grouped them according to the criteria to 
assess the likelihood of the diagnosis of FH. We also calculated the mean 
lipid levels that were taken before the diagnosis and treatment.  
Results: We identified 225 patients with a DLCN score of 6-8 (mean total 
cholesterol: 9.38±3.0 mmol/L, mean LDL-C: 7.61±2.4 mmol/L), and 11 706 
patents with a DLCN score of 3-5 (mean total cholesterol: 7.34±1.2 
mmol/L, mean LDL-C: 5.26±0.8 mmol/L).  
Conclusions: Analyzing more regional and country-wide data and more 
frequent measurements of total cholesterol and LDL-C levels would 
increase the number of the discovered FH cases. Data mining seems to be 
ideal for filtering and screening for FH in Hungary. 
 
 
 
 
 
Highlights 
 There are not exact data about the frequency of familial hypercholesterolemia (FH) in 
Hungary.  
 We aimed to identify patients with FH using data mining methods. 
 Medical records of 1,342,124 patients were included.   
 We calculated Dutch Lipid Clinic Network (DLCN) scores and lipid levels.  
 We identified 11,937 patients with a DLCN score of 3-8.  
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Abstract  
Background and aims: Familial hypercholesterolemia (FH) is one of the most frequent 
diseases with monogenic inheritance. Previous data indicated that the heterozygous form 
occurred in 1:250 people. Based on these reports, around 36,000-40,000 people are estimated 
to have FH in Hungary, however, there are no exact data about the frequency of the disease in 
our country. Therefore, we initiated a cooperation with a clinical site partner company that 
provides modern data mining methods, on the basis of medical and statistical records, and we 
applied them to two major hospitals in the Northern Great Plain region of Hungary to find 
patients with a possible diagnosis of FH.  
Methods: Medical records of 1,342,124 patients were included in our study. From the mined 
data, we calculated Dutch Lipid Clinic Network (DLCN) scores for each patient and grouped 
them according to the criteria to assess the likelihood of the diagnosis of FH. We also 
calculated the mean lipid levels before the diagnosis and treatment.  
Results: We identified 225 patients with a DLCN score of 6-8 (mean total cholesterol: 
9.38±3.0 mmol/L, mean LDL-C: 7.61±2.4 mmol/L), and 11,706 patients with a DLCN score 
of 3-5 (mean total cholesterol: 7.34±1.2 mmol/L, mean LDL-C: 5.26±0.8 mmol/L).  
Conclusions: The analysis of more regional and country-wide data and more frequent 
measurements of total cholesterol and LDL-C levels would increase the number of FH cases 
discovered. Data mining seems to be ideal for filtering and screening of FH in Hungary. 
 
Keywords: Familial hypercholesterolemia, screening, low-density lipoprotein, Dutch Lipid 
Clinic Network Criteria, data mining, deep learning 
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Introduction  
 
 Healthcare data indicate that cardiovascular diseases are the leading cause of death in 
Europe. Hungarian data are even less favorable since, compared to the EU-15 countries, the 
life expectancy is shorter by 6.8 years among men and by 4.8 years among women at the age 
of 40. Indeed, the risk of premature mortality caused by cardiovascular diseases (CVDs) is 
approximately three times higher in the Central Eastern European region than in the Western 
European countries. Additionally, only 5 years are expected to be spent in health after the age 
of 65 in Hungary, while this number is 12.5 years in the three best performing EU states, 
which shows a significant gap versus the developed Western European states 
1,2.  
 Hyperlipidemia is a major risk factor of cardiovascular diseases. Increased blood 
cholesterol levels contribute significantly to atherosclerosis, therefore, diseases resulting in 
excessively elevated cholesterol concentrations lead to premature cardiovascular 
complications even at younger age 
3
. Familial hypercholesterolemia (FH) is one of the most 
frequent diseases with monogenic inheritance caused by various mutations in the genes 
encoding the low-density lipoprotein (LDL) receptor, apolipoprotein (Apo) B100 and the 
proprotein convertase subtilisin/kexin type 9 (PCSK9) 
4
. Previous data indicates that the 
heterozygous form of FH occurs in 1:500 subjects, while the homozygous form develops in 
1:1,000,000 
5
. Recent studies also brought attention to certain populations where familial 
hypercholesterolaemia appears to be more frequent. In Holland, 1 person out of 200 was 
found to have heterozygous FH 
6
; while a recent meta-analysis indicates the FH frequency of 
1:250. FH prevalence appears to vary by age and geographical location 
7
. 10-30 million 
people are estimated to have FH globally, although 80% of the cases are not diagnosed. It has 
to be mentioned that only 10% of the diagnosed patients reach the target LDL level and 
studies indicate that patients with FH die 15 years earlier compared to those without 
8
. Other 
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4 
studies indicate a 3.5-16 times increased risk of coronary artery disease (CAD) and a 5-10 
times increased risk of peripheral arterial disease (PAD) in heterozygous FH patients 
9,10,11
. 
 These data highlight that FH is a major challenge in cardiovascular disease 
prevention. Around 20,000-40,000 people are estimated to have FH in Hungary, however, 
there are no exact data about the frequency of the disease in our country. Therefore, to assess 
its real prevalence in Hungary, we created an online FH registry in 2016 (http://fhreg.hu/). 
The project started with three purposes: (1) to inform the broader (lay) population about the 
disease, (2) to provide information about FH to family doctors emphasizing the screening 
possibilities, (3) to have suspected FH patients registered by physicians. Our FH registry is 
based upon the Dutch Lipid Clinic Network (DLCN) criteria 
12
 and score is calculated using 
the clinical and laboratory data provided by the colleagues. Patients with a possible diagnosis 
of FH are registered to their regional lipid centers, where the final diagnosis is made, together 
with risk stratification, and therapy is initialized. Including the 2 national centers in Budapest 
and Debrecen, there are 18 regional lipid centers in Hungary. Based upon the data mentioned 
above, we estimated the number of patients expected to be registered in each center. Our 
primary goal was to find approximately 10% of the suspected FH patients in the first year 
after commencing the project. We also aimed to gather specific information about the disease 
and to start treatment as soon as possible to improve health statistics and life expectancy in 
the region. After running the project for two years, we found that patient enrollment was not 
satisfactory, thus we looked for other methods to find FH patients in Hungary.  
We initiated a cooperation with a clinical site partner company to utilize their medical 
system framework, which provides modern data mining methods on the basis of medical and 
statistical records and we applied it to two major hospitals in the Northern Great Plain region 
of Hungary. We supposed that we could identify more FH patients and we also targeted to 
test the potential usage and scope of the software. 
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 To identify patients with possible, probable and definite diagnosis of FH, we relied on 
the DLCN criteria, which are based on the family history of the patients, their own clinical 
history, physical signs, untreated LDL-C levels and DNA analysis 
12
. The accessible data 
were poor in family history and DNA analysis, so we focused mainly on the other three 
criteria generated automatically from the databases. Most of the time was spent in the pre-
processing phase to make data comparable from various sources. 
 
 
Materials and methods 
 
 Two leading medical centers, University of Debrecen Clinical Center and County 
Hospital of Szabolcs-Szatmár Bereg, provided access to anonymous medical records for 
software development purposes from the Northern Great Plain region of Hungary. The data 
source contained all medical records from these two centers between January 1, 2007 and 
December 31, 2014. We set up a data mining cooperation with a partner company (Black 
Horse Group Ltd.) to utilize their medical system framework named “AescuLab” 
(www.aesculab.net). First, data were extracted from the clinical record systems after 
anonymization to protect patient privacy. The records included several tables with unique 
identifications per case and patient, but without the possibility to link them to the real pa-
tients. We used open source tools (http://pandas.pydata.org/, http://www.numpy.org/) as well 
as our self-developed scripts and solutions to clean the data and fill the missing or corrupt 
data parts. From all separated data, we built a complete concatenated data source containing 
laboratory cases, textual history data, diagnosis codes and patient statistic data. We also built 
special serializing and buffering methods to process data and avoid obvious memory prob-
lems of this massive data source.  
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 Regular preprocessing steps of any textual information were parsing, stemming 
(http://hunspell.github.io/), bag-of-words (BOW) modelling and ranking of expressions with 
“Term Frequency - Inverse Document Frequency” (TF-IDF) [13] and word2vec (W2V) 
modelling performed in Keras (https://keras.io/) to identify important expressions [14]. The 
BOW models describe a document as a histogram of occurring terms or expressions without 
taking advantage of the sequential structure. This results in robustness in representation and 
invariance in case of comparable documents with different sequential structure. The W2V 
models describe a term or expression in a document with an element in a vector space 
defined by a neural network. These families of models are based on a simple language model 
where the contextual terms determine the actual elements in a sequence utilizing the 
sequential structure. Both models are suitable to identify the importance of the terms and 
expressions in a natural way by ranking them based on their IDF score 13 or their perplexity 
14. Besides, we collected a list of important expressions based on expert knowledge and 
utilized string matching algorithms to overcome regular misspelling and recover expressions 
based on partial information.  
 Since one of the extracted data incorporates regular, unprocessed anamnesis, 
additional pre-processing procedures were necessary, such as text extraction and content 
identification with regular expressions. The resulted data embrace a finite set of expressions 
with a simple indicator of occurrence per record with an additional value in case of medical 
examinations. The list of expressions initially included several million elements, which we 
reduced to 250 thousands with the above mentioned methods. Connecting the records of the 
patients, their cases and diagnoses, we described the medical history as a series of events in 
time associated with the patients. This format allowed us to identify potential patients with 
familial hypercholesterolemia and their medical history of hypercholesterolemia ranked by 
Dutch criteria.  
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7 
 From the mined data, we calculated DLCN scores for each patient and grouped them 
according to the criteria to assess the likelihood of the diagnosis of FH. We also calculated 
the mean lipid levels of the patients before the diagnosis and treatment. 
 
Results 
 
 Medical records of 1,342,124 patients were included in our study: 44% of the records 
were retrieved from University of Debrecen Clinical Center and 56% of them were accessed 
from County Hospital of Szabolcs-Szatmár Bereg. First, we assigned patients into 9 separate 
groups as it is depicted in Table 1. Group 1 contains the number of patients with a diagnosis 
of FH, using mined textual history data. This group was really small and provided acceptable 
results only in Debrecen. Group 2 contains patients with a hypercholesterolemia diagnosis; 
groups 3,4,5 represent patients with CAD, cerebrovascular disease and PAD, respectively. 
Groups 6,7 are for those with tendinous xanthoma and corneal arcus diagnoses, respectively. 
We only used cases strongly supported by textual data to ensure likelihood of the diagnosis. 
Group 8 represents the set of those individuals with LDL-C levels above 3.4 mmol/L and 
triglyceride levels below 1.7 mmol/L (averages are calculated before statin treatment); while 
group 9 encompasses patients with total cholesterol levels above 5.2 mmol/L and triglyceride 
concentrations below 1.7 mmol/L triglyceride level (averages are calculated before statin 
treatment).  
From the mined data, we calculated DLCN scores for each patient and grouped them 
according to the criteria to assess the likelihood of the diagnosis of FH (Table 2). Our data 
indicate that 0.89% of the hospital patients might be affected by FH in the Northern Great 
Plain region of Hungary. We also assessed the prevalence of other CVD risk factors in the 
patients, including current smoking, hypertension, any type of diabetes mellitus, chronic 
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8 
kidney disease and obesity (defined as body mass index over 30 kg/m
2
), low HDL-C levels 
and hypothyroidism (Table 3). However, this data might not cover the full population, due to 
the potentially increased hospitalization in the elderly. Indeed, the number of the yearly 
medical cases is lower at younger ages, as it is 7.1 below 18 years (cases also include births); 
6.99 between years 19-30; with an increasing number of 12.09 yearly cases between years 
31-60; topping it with 19.96 hospital cases above 61 years. It has to be noted that the age 
distribution of the hospital patients is very similar to that of the regional population according 
to the 2011 Census in Hungary (data provided by the Hungarian Central Statistical Office) 
(Fig.1).  
 We were unable to assess data of family history and DNA analysis, but we assume 
that it would not have altered the number of patients with 3+ DLCN score significantly. Hun-
garian Central Statistical Office data indicates that 76% of the total population appears at 
least once at the hospital each year. In a previous study, patients fulfilling the strict criterion 
of clinical definite, probable or possible FH according to the Dutch criteria were offered mo-
lecular genetic analysis, but only 33% of patients have been identified as mutation carriers 
15
. 
Thus one might suspect that 1 every 340 subjects might be affected with familial hypercho-
lesterolemia in our region. 
 
Discussion 
We report the results of the first Hungarian FH screening project utilizing modern 
data mining methods, on the basis of medical and statistical records, at two major hospitals in 
the Northern Great Plain region of Hungary. 225 patients with probable diagnosis of FH, and 
11,706 patients with possible diagnosis using the calculated DLCN scores.  Although this 
study is not eligible to provide exact data on FH prevalence in Hungary, an estimated 
prevalence was calculated and found to be 1:340, which is in line with the prevalence data of 
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9 
some other European countries 
16
. Being one of the most frequent monogenic disorders, 
familial hypercholesterolemia represents a major challenge in cardiovascular disease 
prevention. Acknowledging its significance, the United States (US) Make Early Diagnosis to 
Prevent Early Deaths (MEDPED) diagnostic criteria were elaborated 
17
. Hungary also joined 
this program, however, the general opinion was that diagnosing FH would not significantly 
alter its treatment due to the lack of effective therapeutic tools at the time. Some previous 
studies drew the attention on the fact that the prevalence of FH might be higher in Europe, 
compared to the previous estimates 
18, 19
. Besides these results, newly developed drugs have 
also contributed to boost screening efforts and more effective therapies in FH. Indeed, the 
discovery of PCSK9 protein and its role in lipid metabolism provided a new treatment target. 
Subsequently, PCSK9 inhibitors were widely found to be effective in lowering cholesterol 
levels and to promote increasing efforts to identify FH patients who would benefit from more 
effective lipid lowering 
20
. 
 Hungary has become a member of the EAS-FH Studies Collaboration (FHSC) 
21
 and 
takes part in the ScreenPro FH program, as well 
22
. Aiming at improving FH awareness in 
Hungary, we have initiated a nationally coordinated FH screening program with the help of 
regional and national lipid centers in Hungary. The leaders of the regional centers are 
responsible for providing extensive information about FH to the lay population and for 
educating medical staff in the region, including nurses, assistants and physicians. National 
coordinators oversee the efforts of regional centers, provide effective media appearance and 
focus on building international relations. In the frame of this program, we joined the FH 
Week 2017 in Hungary and participated in several radio, television as well as print and online 
appearances. 
 Despite the efforts, we realized that registering patients was slow; therefore, to 
identify more FH patients in our region, we analyzed the cases of two leading medical centers 
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10 
and estimated the number of patients with a potential diagnosis of FH. Sampling was not 
representative, although it covered a large number of individuals (about three fourths of the 
population). Obesity, diabetes mellitus and low HDL-C levels tended to be more frequent 
among patients with DLCN scores above 8, while other CVD risk factors as smoking, 
hypertension chronic kidney disease were found to be less prevalent in these patients. We 
also tried to assess the prevalence of familial hypercholesterolemia with the help of data 
provided by the national statistical office. Although there is no data about the exact number 
of the FH prevalence in Hungary, we suspected to find more patients with a potential 
diagnosis of FH analyzing these cases.  
Weaknesses of the study may answer, at least in part, these results. Although it is 
suggested to adjust LDL-C levels to calculate DLCN scores in patients receiving lipid 
lowering treatment 
18
, we were unaware of whether general practitioners (GPs) had initiated 
therapy or not before patient referral; therefore, we calculated the mean lipid levels that were 
taken prior to the diagnosis and treatment proposed in the medical centers. Recent reports 
indicate that GPs are able to accurately identify FH patients using DLCN scores 
23,24
; though, 
as a result of the regulations of the Hungarian national health system, financing issues and the 
general lack of LDL-C measurements in the community laboratories, general practitioners are 
disposed to refer hyperlipidemic patients early to the hospital, also to organize risk 
stratification. 
We were unable to assess data of family history and genetic data, moreover, it has to 
be mentioned that not 100% of the population goes to hospital each year. In addition, hospital 
goers tended to be older and those who visited a hospital tended to be checked more 
frequently. On the contrary, younger patients usually had less thorough laboratory 
examinations and their history was asked less frequently. These tendencies mean that 
identifying FH patients is biased towards the elderly.  
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11 
 On the other hand, frequent hospital visits in our region can be considered as a 
strength of our study as it might help increase the chance of finding FH patients. Analyzing 
more regional and country-wide data and a higher prevalence of total cholesterol and LDL-C 
measurements would increase the number of discovered FH cases. Additionally, better 
interoperability of electronic health records are recommended, since data comparability is of 
major interest to effectively utilize software applications to identify potential FH patients 
25
. 
Family history and genetic data, as structured data elements in health records as well as 
mapping family networks with the consent of the hyperlipidemic patients and FH probands, 
would improve disease awareness and detection.  
Data mining seems to be ideal for filtering and screening both single and mass cases, 
though valid diagnoses of FH require thorough medical workup. As a next step, we would 
like to apply modern machine learning (Gradient Boosting Liu 26, Support Vector Machines 
27
 
or recurrent and sequential Artificial Neural Networks 
28
) methods to better understand the 
connections between expressions while predicting risk of FH based on medical time-series.  
 For the treatment, the 6
th
 Hungarian Cardiovascular Consensus Conference stratified 
FH into the very-high risk category with a target LDL-C level of 1.8 mmol/L. The latest, 7
th
 
Hungarian Cardiovascular Consensus Conference kept FH as an option in the very-high risk 
category since the 2016 EAS/ESC Guideline 29 considered FH without CVD as only high-
risk. FH is treated with statins in the first line, while statin + ezetimibe combination and LDL 
apheresis are for those not reaching LDL-C target levels. To date, PCSK9 inhibitors are not 
subsidized in Hungary, therefore, their wider availability is ponderous.  
Our data, though, might help increase FH screening efforts in our region, thus 
improving the therapeutic opportunities and life expectancy of our patients. Local activities 
including better cooperation between GPs, laboratories and medical centers 
30
, uniform and 
comparable electronic health records, as well as wider regional and international cooperation, 
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12 
such as EAS-FHSC 21 and ScreenPro FH 
22
 could contribute to these efforts. Effective 
screening and early treatment of FH might also improve the miserable cardiovascular 
mortality data in Hungary. 
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Table 1. Number and lipid parameters of patients assigned to groups by age, clinical and laboratory parameters 
  Age (years) Lipid parameters 
 Grouping +18 19-30 ♀ 31-60 
♂ 31-55 
♀ 61+ 
♂ 56+ 
Total Total 
cholesterol 
(mmol/L) 
LDL-C 
(mmol/L) 
HDL-C 
(mmol/L) 
Group 1 With a diagnosis of FH, 
history data 
11 10 69 45 135 7.90 ± 1.66 5.56 ± 1.55 1.41 ± 0.29 
Group 2 Diagnosis of 
hypercholesterolemia  
80 357 13428 13552 27387 6.69 ± 1.61 4.71 ± 1.37 1.44 ± 0.44 
Group 3 Coronary artery disease  67 363 10245 16883 27558 5.47 ± 1.55 3.48 ± 1.29 1.26 ± 0.40 
Group 4 Cerebrovascular disease 167 608 15779 33416 49970 6.27 ± 1.61 4.70 ± 1.28 1.42 ± 0.43 
Group 5 Peripheral arterial disease 23 109 13373 48450 61955 6.39 ± 1.82 4.91 ± 1.26 1.45 ± 0.43 
Group 6 Tendinous xanthoma  1 2 5 7 15 5,26 ± 0,90 3,15 ± 0,63 1,47 ± 0,52 
Group 7 Corneal arcus 3 8 35 34 80 5,69 ± 1,75 3,81 ± 1,54 1,45 ± 0,25 
Group 8 LDL-C > 3.4 mmol/L and 
triglyceride < 1.7 mmol/L 
71 282 6563 4559 11475 7.67 ± 1.01 5.45 ± 0.77 1.60 ± 0.42 
Group 9 Cholesterol levels >5.2 
mmol/L and triglyceride       
< 1.7 mmol/L 
107 492 9441 6918 16958 7.90 ± 1.02 5.47 ± 0.91 1.68 ± 0.46 
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Table 2. Lipid parameters of patients categorized according to the Dutch Lipid Clinic Network criteria 
 DLCN 
score 
number of 
patients 
Ratio 
(%) 
Total cholesterol 
(mmol/L) 
LDL-C ( mmol/L) HDL-C (mmol/L) 
Definite FH  >8 6 0.001 10.3 ± 0.7 8.1 ± 0.6 2.42 ± 0.4 
Probable FH 6-8 225 0.017 9.38 ± 3.0 7.61 ± 2.4 1.54 ± 0.6 
Possible FH 3-5 11706 0.87 7.34 ± 1.2 5.26 ± 0.8 1.58 ± 0.4 
Total >3 11937 0.89    
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Table 3. Prevalence of cardovascular risk factors in patients categorized according to the Dutch Lipid Clinic Network criteria 
 
 
 DLCN 
score 
Number of 
patients 
Ratio (%) 
Current 
smoker (%) 
Hypertension 
(%) 
Diabetes 
mellitus 
(%) 
Chronic 
kidney 
disease (%) 
Obesity 
(%) 
Low HDL-C 
level (%) 
Hypothyroidis
m (%) 
Definite FH >8 6 0,001 16.9 65.5 23.2 21.4 8.9 25.7 8.9 
Probable 
FH 
6-8 225 0,017 18.5 71.3 21.8 30.6 5.6 19.0 10.5 
Possible FH 3-5 11706 0.87 16.2 70.6 21.9 17.7 7.1 16.3 9.4 
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Figure legend 
 
Figure 1. Demographics of hospital visitors vs. regional population in the Northern Great 
Plain region of Hungary. 
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Dear Sirs, 
 
We have received the editorial response and the reviewers’ comments and questions regarding our 
manuscript titled “Identifying patients with familial hypercholesterolemia using data mining 
methods in the Northern Great Plain region of Hungary" (ATH-D-18-00393). Thank you for the 
opportunity to submit our revised manuscript to your journal. 
 
Below, please find our answers to the questions and comments. As it was requested, changes in the 
revised manuscript are highlighted in red. (We also submit the final corrected version of the 
manuscript.) 
 
 
Reviewer #1: 
We thank you for the thorough review and for the comments aimed to improving our manuscript. In 
the followings, we respond to your suggestions one by one. 
 
Although there are limitations in data accumulation that have been adressed in the text, this paper 
gives nonconfirmatory information about FH prevalance in Hungary. 
1-The following sentence needs to be moved to methods section: We initiated a cooperation with a 
clinical site partner company (Black Horse Group Ltd.) to utilize their medical system framework 
named "AescuLab" (www.aesculab.net).  
 
As requested, we rephrased the above mentioned sentence and moved it into the methods section 
(page 5): 
“We set up a data mining cooperation with a partner company (Black Horse Group Ltd.) to utilize 
their medical system framework named “AescuLab” (www.aesculab.net)." 
 
2-The following sentence implies that the EAS/ESC guideline categorises FH as very high risk 
whereas FH without ASVD is only high risk in the guideline,this should be corrected: The latest, 
*Point-by-Point Response
  
7thHungarian Cardiovascular Consensus Conference kept FH as an option in the very-high risk 
category according to the 2016 EAS/ESC Guideline 
 
Thank you for the comment, we corrected the following sentence (page 11) to: 
“The latest, 7th Hungarian Cardiovascular Consensus Conference kept FH as an option in the very-
high risk category since the 2016 EAS/ESC Guideline 
29
 considered FH without CVD as only high-
risk.” 
 
Thanking for your comments, we do hope that our modifications will meet your expectations. 
 
 
Reviewer #2:  
This is an excellent example of combination of review and original article, with new, 
national/regional based very robust data (more than 1 300 000!). Authors clearly demonstrate the 
practice of examining large databases in order to generate new information on the example of FH. 
Paper is relatively short, condensed, the tables are easy to read and understand. Theoretically we 
could speculate about the difference between the region of Grate Plate and the capital of Hungary 
from FH prevalence point of view, but authors conclude sophistically conclude and comment their 
results. 
In my mind this article can be published in the "Special FH issue", without revision. 
 
Thanking you for your comments, we are honestly grateful for your recommendation. 
 
 
Editors' comments: 
 
This is the first attempt to define the frequency of FH in Hungary. The approach is based on 
interrogated hospital records and generates useful information. With these types of analysis the 
issue is false positives due to other conditions that cause high cholesterol. Can authors add 
information on diabetes, obesity and CKD; were secondary causes of high cholesterol such 
hypothyroidism also excluded ? What about other CV risk factors? Smoking, low HDL, 
hypertension ? Please try to include. 
 
  
With our cordial thankfulness, we calculated the prevalence of the conditions mentioned above and 
added a sentence in the Results section (page 7) and a new table (Table 3) into the manuscript. We 
also addressed this issue in the Discussion (page 10). 
 
Sentence in Results: ”We also assessed the prevalence of other CVD risk factors in the patients, 
including current smoking, hypertension, any type of diabetes mellitus, chronic kidney disease and 
obesity (defined as body mass index over 30 kg/m
2
), low HDL-C levels and hypothyroidism (Table 
3).” 
 
Table: 
”Table 3. Prevalence of cardovascular risk factors in the patients categorized according to Dutch 
Lipid Clinic Network criteria” 
 
 
DLCN 
score 
numbe
r of 
patient
s 
ratio 
(%) 
current 
smoker 
(%) 
hyperten
sion (%) 
diabet
es 
mellit
us (%) 
chronic 
kidney 
disease 
(%) 
obesit
y (%) 
low 
HDL-C 
level 
(%) 
hypothyroi
dism (%) 
Definite 
FH 
>8 6 0,001 16.9 65.5 23.2 21.4 8.9 25.7 8.9 
Probabl
e FH 
6-8 225 0,017 18.5 71.3 21.8 30.6 5.6 19.0 10.5 
Possible 
FH 
3-5 11706 0.87 16.2 70.6 21.9 17.7 7.1 16.3 9.4 
 
 
Sentence in Discussion: ”Obesity, diabetes mellitus and low HDL-C levels tended to be more 
frequent among patients with DLCN scores above 8, while other CVD risk factors as smoking, 
hypertension chronic kidney disease were found to be less prevalent in these patients.” 
 
 
The authors indicate that an adjustment of treated lipids was made to assess DLCNS; was this for 
LDL-C; if so, how was this estimated ? refs required.  
 
Since we had no information about the general practitioners’ efforts (or the lack of them) about 
indicating lipid lowering treatment, we calculated the means of lipid parameters that were taken 
before the diagnosis and treatment that were proposed in the hospitals. Generally, Hungarian 
general practitioners tend to refer hyperlipidemic patients early to lipid centers. Considering that the 
  
patients usually don’t have wait more than 3-4 weeks, we believe that lipid lowering treatment 
initialized by the family doctors wouldn’t have modified our data significantly. We addressed this 
issue as the followings (page 10):  
”Although it is suggested to adjust LDL-C levels to calculate DLCN scores in patients receiving 
lipid lowering treatment 
18
, we were unaware of whether general practitioners (GPs) had initiated 
therapy or not before patient referral; therefore, we calculated the mean lipid levels that were taken 
prior to the diagnosis and treatment proposed in the medical centers.”  
 
2 others points: 
1. The deficiency that primary care was not studied needs pointing out and references made to 
relevant studies from UK and Australia, both published on Heart. Most FH is in community; what 
is happening in Hungary? 
 
Since this important issue closely relates to the subject that was addressed above, we continued our 
text in the manuscript as it follows (page 10). We also added new references to highlight the 
importance of the topic (refs 23, 24).  
”Recent reports indicated that GPs were able to accurately identify FH patients using DLCN scores 
23,24
; though, resulting from the regulations of the Hungarian national health system, financing 
issues and the general lack of LDL-C measurements in the community laboratories, general 
practitioners are disposed to refer hyperlipidemic patients early to the hospital, also for organizing 
risk stratification. 
 
 
2. Safarova has published a good article in Circulation Research 2018 on use of health information 
technology and how this approach aligns with that used by authors in detecting FH is apposite and 
should be referenced and noted in Discussion. 
 
This is also a very important comment, since databases of electronic health records are very hard to 
compare and making them comparable is extremely time consuming. Thanking for your suggestion, 
we referenced this paper in the manuscript (ref 25) and added the following section in the 
Discussion (page 11): 
”Additionally, better interoperability of electronic health records would be recommended, since 
data comparability is of major interest to effectively utilize software applications in identifying 
potential FH patients 
25
. Family history and genetic data as structured data elements in health 
  
records as well as mapping family networks with the consent of the hyperlipidemic patients and FH 
probands would improve disease awareness and detection.” 
 
To briefly summarize these issues we added the followings into the penultimate sentence of the 
manuscript (page 11) with the help of a new reference (ref 30): 
”Local activities including better cooperation between GPs, laboratories and medical centers 30, 
uniform and comparable electronic health records, as well as wider regional and international 
cooperation, such as EAS-FHSC 
21
 and ScreenPro FH 
22
 could contribute to those efforts.” 
 
 
The new references of the manuscript are Refs 23, 24, 25, and 30, respectively: 
 
[23] Bell, DA, Kirke, AB, Barbour, R, et al., Can patients be accurately assessed for familial 
hypercholesterolaemia in primary care?, Heart Lung Circ, 2014;23:1153-1157. 
24] Kwok, S, Pang, J, Adam, S, et al., An online questionnaire survey of UK general 
practitioners' knowledge and management of familial hypercholesterolaemia, BMJ Open, 
2016;6:e012691. 
[25] Safarova, MS and Kullo, IJ, Lessening the Burden of Familial Hypercholesterolemia Using 
Health Information Technology, Circ Res, 2018;122:26-27. 
[30] Kirke, AB, Barbour, RA, Burrows, S, et al., Systematic detection of familial 
hypercholesterolaemia in primary health care: a community based prospective study of three 
methods, Heart Lung Circ, 2015;24:250-256. 
 
We also corrected some typos. 
 
 
In sum, we would like to express our gratitude to the reviewers and to the editor for their insightful 
comments to improve the quality of our manuscript. We hope our revised manuscript will fulfil the 
requirements of the journal and will be worth publishing. 
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György Paragh 
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